Clinical, Cosmetic and Investigational Dermatology最新文献

{"title":"Review of Excessive Cytosolic DNA and Its Role in AIM2 and cGAS-STING Mediated Psoriasis Development.","authors":"Tongtong Xu, Xiaojing Zhong, Nana Luo, Wenyi Ma, Pingsheng Hao","doi":"10.2147/CCID.S476785","DOIUrl":"10.2147/CCID.S476785","url":null,"abstract":"<p><p>In psoriasis, keratinocytes are triggered by factors, such as infection or tissue damage, to release DNA, which thereby activates plasmacytoid dendritic cells and macrophages to induce inflammation, thickened epidermis, and parakeratosis. The recognition of double-stranded (ds)DNA facilitates the activation of cytoplasmic DNA sensors absent in melanoma 2 (AIM2) inflammasome assembly and cyclic guanosine monophosphate adenosine monophosphate (cGAMP) synthase (cGAS) - stimulator of interferon gene (STING) pathway, both of which play a pivotal role in mediating the inflammatory response and driving the progression of psoriasis. Additionally, secreted proinflammatory cytokines can stimulate further DNA release from keratinocytes. Notably, the activation of AIM2 and cGAS-STING signaling pathways also mediates programmed cell death, potentially enhancing DNA overproduction. As a result, excessive DNA can activate these pathways, amplifying persistent inflammatory responses that contribute to the maintenance of psoriasis. Several studies have validated that targeting DNA and its mediated activation of AIM2 and cGAS-STING offers promising therapeutic strategies for psoriasis. Here, we postulate a hypothesis that excessive cytosolic DNA can activate AIM2 and cGAS-STING, mediating inflammation and programmed cell death, ultimately fostering DNA accumulation and contributing to the development of psoriasis.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2345-2357"},"PeriodicalIF":1.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Randomized Trial Comparing Quality of Life in Adult Female Acne Treated with Azelaic Acid 15% Gel versus Oral Spironolactone.","authors":"Diogo Pazzini Bomfim, Marco Alexandre Dias da Rocha, Adriana Sanudo, Edileia Bagatin","doi":"10.2147/CCID.S463295","DOIUrl":"https://doi.org/10.2147/CCID.S463295","url":null,"abstract":"<p><strong>Introduction: </strong>In several countries, recent research has shown an increase in the prevalence of adult female acne (AFA), defined as the acne that appears in women aged over 25. This disease brings some particularities and challenges, such as a greater impact on quality of life (QoL) and chronicity. A negative impact on QoL has been observed, as well as anxiety, depression, anger, low self-esteem, and feelings of embarrassment and frustration.</p><p><strong>Purpose: </strong>To quantify AFA's impact on QoL and the influence of two dermatological treatments.</p><p><strong>Material and methods: </strong>A prospective study including 40 women, aging from 25 to 44 years old, with mild-to-moderate acne was conducted. Participants underwent clinical, laboratory, and photographic evaluations. They were randomized into two treatment groups: group 1 - azelaic acid (AZA) 15% gel twice daily; group 2 - spironolactone (SPIRO) 100 mg/day and treated for 6 months. At baseline and at the end of treatments, a specific QoL questionnaire for acne, already translated and validated for Brazilian Portuguese (Acne-QoL-BR), was applied. It contains 19 questions allotted in four domains. Each item within a domain is scored from 0 to 6. The total score ranges from 0 to 114 and domains are distributed as follows: 0-30 (self-perception), 0-30 (role-emotional), 0-24 (role-social), 0-30 (acne-symptoms). Higher scores reflect better QoL.</p><p><strong>Results: </strong>The mean age was 32.7 (SD: 5.42); 85% presented persistent acne. After treatment regardless of group, there was a significant improvement in total score and all domains' scores of acne QoL-BR (p < 0.001), with no difference between groups, despite one treatment being topical and the other systemic (p=0.918).</p><p><strong>Conclusion: </strong>Acne-QoL-BR is a useful tool for quantifying the impact of acne and should be used as an efficacy parameter in clinical trials.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2335-2343"},"PeriodicalIF":1.9,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Risk Factors for Death from Melanoma and Genitourinary Diseases in Male Patients with Cutaneous Melanoma: A Cohort Propensity Score Matching Study.","authors":"Kaijie Wang, Weiwei Wu, Yongbao Wei, Xianwei Cao","doi":"10.2147/CCID.S482389","DOIUrl":"10.2147/CCID.S482389","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the influencing factors of male cutaneous melanoma (CM) patients dying from genitourinary diseases (GUD).</p><p><strong>Methods: </strong>We searched the surveillance, epidemiology, and end results (SEER) database and extracted data on male CM patients according to the inclusion and exclusion criteria, including male patients whose cause of death was CM (cohort A) or GUD (cohort B). Comparisons between the two cohorts were performed before and after propensity score matching (PSM). An interaction analysis between age and year of diagnosis was also conducted. Cox regression analysis were performed to find the risk factors for death from GUD.</p><p><strong>Results: </strong>Seven thousand seventy-eight CM patients were included, including 6415 (90.6%) in cohort A and 663 (9.4%) in cohort B. Compared with cohort A, cohort B patients were older (median age 74 ys. vs 65 ys.) and were more under the localized stage and had longer survival time no matter before or after PSM (all p<0.001). The stage was an inhibitory factor for cohort B (p <0.001). After PSM, only age and year of diagnosis were found to be cohort B's promoting factors (p<0.001). The interaction analysis showed that older patients diagnosed in later years (2009-2020) had a higher risk of dying from GUD compared to those diagnosed earlier (p<0.05). Patients with a later year of diagnosis (2009-2020) had a lower median survival time than patients with an earlier year of diagnosis (2000-2008) (p<0.001). When the patient's year of diagnosis was earlier (2000-2008), older patients (>75 ys.) had a higher risk of dying from GUD than younger patients (≤75 ys.) (p<0.001).</p><p><strong>Conclusion: </strong>We first reported a significant interaction between age and year of diagnosis in male CM patients dying from GUD, highlighting the increased risk in older patients diagnosed more recently. We may pay attention to the possibility of dying from genitourinary diseases for CM patients.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2323-2333"},"PeriodicalIF":1.9,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating the Latin American Aesthetic Patient: A Review.","authors":"Ada Regina Trindade de Almeida, Patricia E Garcia, Raul Banegas, Silvia Zimbres, Carolina Martinez, Jan Frolik, Camila Cazerta de Paula Eduardo","doi":"10.2147/CCID.S482551","DOIUrl":"10.2147/CCID.S482551","url":null,"abstract":"<p><p>The rich and diverse heritage of Latin American people contributes to a large variety of physical features, which translates to a patient population with a range of motivations for seeking cosmetic procedures and unique perspectives that influence their aesthetic preferences. As there is no one standard of beauty, it is important for physicians to understand the various factors that influence their patients' perceptions of beauty and desires to seek cosmetic treatment, especially because patient preference may differ from the physician perspective. Physicians in Latin America must consider the demographic, ethnic, and cultural factors that influence their patients to ensure culturally sensitive treatment approaches, natural-looking results, and patient satisfaction. This review includes a discussion of published literature, combined with the expert opinion of the authors, to provide a detailed description of the elements that impact aesthetic perceptions of patients living across the Latin American diaspora and highlights important gaps in research for future studies to address.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2311-2321"},"PeriodicalIF":1.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Melasma During Pregnancy: Risk Factors and Photoprotection-Focused Strategies.","authors":"Leilei Zhao, Xinmeng Fu, Hongbin Cheng","doi":"10.2147/CCID.S488663","DOIUrl":"10.2147/CCID.S488663","url":null,"abstract":"<p><p>Melasma is a benign but emotionally distressing skin condition that reduces patients' quality of life, with prevalence rates during pregnancy ranging from 36.4% to 75%. Troublingly, up to 30% of cases are reported to persist after delivery, even ten years later. And recurrence and aggravation are common in subsequent pregnancies. This review examines the risk factors and mechanisms associated with melasma during pregnancy and summarized corresponding preventive strategies. We emphasize the critical role of photoprotection, including the use of sunscreens from the first trimester, in reducing the incidence of melasma.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2301-2310"},"PeriodicalIF":1.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of a Dermocosmetic Cream as an Adjunct to Adapalene for Mild and Moderate Acne in Indonesia: Results of a Multicenter Randomized Controlled Study.","authors":"Irma Bernadette S Sitohang, Lilik Norawati, Satya Wydya Yenny, Arie Kusumawardani, Sinta Murlistyarini, Silvia Veronica Setiawan, Aria Kekalih, Gladys Riany, Delphine Kerob","doi":"10.2147/CCID.S474331","DOIUrl":"10.2147/CCID.S474331","url":null,"abstract":"<p><strong>Purpose: </strong>Acne is a chronic inflammatory skin condition affecting mainly teenagers and adults as well. Guidelines recommend retinoids as a first-line treatment for mild-to-moderate acne. However, dermocosmetics in adjunct could potentially improve efficacy and tolerability. This study was conducted to determine the effectiveness and safety of a dermocosmetic cream containing salicylic acid, lipohydroxy acid, niacinamide, <i>Aqua posae filiformis</i>, procerad and zinc salt in the treatment of mild-to-moderate acne vulgaris in adjunct to different regimens of adapalene compared to adapalene only.</p><p><strong>Patients and methods: </strong>This randomized, controlled, parallel-group, evaluator-blind study was conducted over 8 weeks on male and female acne subjects at five teaching hospitals in Indonesia. A total of 291 participants were enrolled and divided into three treatment groups: Group A adapalene 0.1% cream nightly - Group B dermocosmetic cream daily + adapalene 0.1% cream every two nights - Group C dermocosmetic cream daily + adapalene 0.1% cream nightly. Clinical evaluations of treatment included scoring on Global Evaluation of Acne (GEA) scale, lesion count (Indonesian Acne Expert Meeting scale), treatment tolerability and treatment satisfaction. Evaluations were performed on Day 28 and Day 56 of treatment.</p><p><strong>Results: </strong>After 28 and 56 days of treatment, all groups exhibited improvements across the various measures. Data analysis, utilizing Anova for repeated measurements, revealed a statistically significant difference between Groups C and A for reduction of GEA scores (p = 0.038) in favor of Group C. On Day 56, percentages of subjects with GEA Scale improvements of at least 1 grade in comparison with baseline were in Group C (61.7%) followed by Group A (47.9%) and Group B (45.3%). Better treatment tolerance and satisfaction scores were noted in Groups B and C.</p><p><strong>Conclusion: </strong>Combination of the dermocosmetic cream with adapalene showed higher efficacy, tolerability and satisfaction in comparison to adapalene alone.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2283-2296"},"PeriodicalIF":1.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient.","authors":"Vito Di Lernia, Francesca Peccerillo","doi":"10.2147/CCID.S483166","DOIUrl":"10.2147/CCID.S483166","url":null,"abstract":"<p><p>Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory skin disease characterised by follicular keratotic papules and perifollicular erythema coalescing into orange-red scaly plaques, and palmoplantar keratoderma. Characteristic islands of sparing are usually observed. A standardised therapeutic approach is lacking owing to the infrequent occurrence of this disease. However, anti-interleukin (IL)-17 and anti-IL-23 therapies have recently emerged as effective therapies in patients affected by PRP, with improvements in severity scores, change in severity of erythema, scaling, and thickness of lesions. Here, we report a 43-year old, female breast cancer who developed severe refractory PRP, which greatly impacted her quality of life. The patient experienced a marked improvement after treatment with tildrakizumab. Treatment was stopped after one year, and the three-year follow-up did not show relapse. In conclusion, 52- week treatment with tildrakizumab, an IL-23 antagonist, proved to be a favourable treatment option for PRP, leading to good patient adherence, improvement in quality of life, and long-term follow-up without relapse.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2297-2300"},"PeriodicalIF":1.9,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eccrine Porocarcinoma in Linear Epidermal Nevus.","authors":"Qiuli Zhang, Jianmin Chang","doi":"10.2147/CCID.S490766","DOIUrl":"10.2147/CCID.S490766","url":null,"abstract":"<p><p>Linear epidermal nevus is a congenital focal epidermal dysplasia common at birth or during childhood. Linear epidermal nevus followed by cutaneous malignancy is extremely rare. Here, a case of linear epidermal nevus followed by eccrine porocarcinoma (EPC) is reported.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2273-2276"},"PeriodicalIF":1.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estradiol Valerate Tablets Caused Rare Severe Drug Eruption: The First Reported Case.","authors":"Fang Yang, Yuedan Xu, Xiangyu Li","doi":"10.2147/CCID.S495269","DOIUrl":"10.2147/CCID.S495269","url":null,"abstract":"<p><p>Severe drug eruption is a severe allergic reaction to a drug, usually due to irritation with certain drugs. It may be present as a generalized erythematous maculopapular rash, a pleomorphic rash, with or without blisters and ulcers. To the best of our knowledgeto date, there is no report of estradiol valerate-induced severe drug eruption. A case of rare severe drug eruption after taking estradiol valerate tablets was first reported to promote clinical drug safety management, especially for rare severe adverse reactions. Meanwhile, it is speculated that estrogen dermatitis might be associated with dendritic cell-mediated allergic mechanisms, inflammation-induced expression of estrogen receptor β, and elevated estrogen levels during pregnancy, according to previous studies. Therefore, pregnant women using this drug need to be focused on. Early and systemic use of glucocorticoids is beneficial to the outcome and prognosis of the disease. It highlights the need for clinicians to be vigilant about rare but serious adverse drug reactions, even with medications that are generally considered safe.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2277-2281"},"PeriodicalIF":1.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying the Genetic Associations Between Diabetes Mellitus and the Risk of Vitiligo.","authors":"Lingyun Zhao, Meng Hu, Li Li","doi":"10.2147/CCID.S480199","DOIUrl":"https://doi.org/10.2147/CCID.S480199","url":null,"abstract":"<p><strong>Purpose: </strong>While increasing observational studies have suggested an association between diabetes mellitus (DM) and vitiligo, the causal relationship and possible mechanism remain unclear.</p><p><strong>Methods: </strong>Publicly accessible genome-wide association study (GWAS) was utilized to conduct a bidirectional two-sample Mendelian randomization (MR) analysis. GWAS data for diabetes and vitiligo were obtained from the UK Biobank Consortium (20203 cases and 388756 controls) and the current GWAS data with largest cases (GCST004785, 4680 cases and 39586 controls) for preliminary analysis, respectively. Inverse variance weighting (IVW) was used as the main analysis method. Several sensitivity analyses were utilized to test the pleiotropy or heterogeneity. To explore the possible mechanism of gene-generating effects represented by the final instrumental variables in the analysis, enrichment analysis was conducted using the DAVID and STRING database.</p><p><strong>Results: </strong>IVW method showed a significant genetic causal association between DM and vitiligo (OR = 1.20, 95% CI: 1.08-1.33, P_IVW = 0.0009). Diabetes subtype analysis showed that T2D (type 2 diabetes) were associated with an increased risk of vitiligo (OR = 1.13, 95% CI: 1.00-1.27, P_IVW = 0.0432). Sensitivity analysis further confirmed the robustness of the results. The enrichment analysis revealed that the genetic inducing effects of diabetes mellitus on vitiligo were primarily about pancreatic secretion and protein digestion and absorption pathway.</p><p><strong>Conclusion: </strong>Our findings provide genetic evidence that there is a notable association between T2D and an elevated risk of vitiligo in European populations. This result may explain why the co-presentation of T2D and vitiligo is often seen in observational studies, and emphasize the significance of vigilant monitoring and clinical evaluations for vitiligo in individuals diagnosed with T2D. The aberrant glucose and lipid metabolism and the primary nutrient absorption disorder of vitiligo brought on by diabetes may be the potential mechanisms behind this association.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"17 ","pages":"2261-2271"},"PeriodicalIF":1.9,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}